A bombshell South Korean study published last week in Biomarker Research, a Springer Nature journal, has ignited fierce debate, suggesting COVID-19 vaccines and boosters (both mRNA and non-mRNA) correlate with a 27% higher overall cancer risk, plus spikes in six specific types: breast (20%), colorectal (28%), gastric (34%), lung (53%), prostate (69%), and thyroid (35%). Drawing from over 8.4 million adults in South Korea's National Health Insurance database (2021-2023), the retrospective cohort tracked participants for one-year post-vaccination, using propensity score matching to compare vaccinated (split by boosters) vs. unvaccinated groups. While mainstream critics like MedPage Today slam it as "flawed" due to short follow-up and potential biases, experts such as epidemiologist Nicolas Hulscher and oncologist Dr. Angus Dalgleish hail it as a wake-up call, arguing spike protein's "carcinogenic" potential demands vaccine withdrawal. This isn't isolated; it echoes an Italian cohort of ~300,000 showing 23% higher cancer hospitalisation post-vaccination. With global jabs nearing 70% coverage, the stakes are existential, is this association causal, or confounded?
Study Design and Shocking Findings: A Nationwide Snapshot
Researchers from Seoul's Ewha Womans University analysed data from 8,407,849 individuals, narrowing to ~3 million via 1:4 matching for age, sex, comorbidities, income, and prior COVID infection. Vaccinated cohorts (mRNA like Pfizer/Moderna; cDNA like AstraZeneca/J&J; mixed) were followed from jab date; unvaccinated from a comparable start. Key: Statistically significant hazard ratios (HRs) across all platforms, with boosters amplifying risks (e.g., 125% for pancreatic cancer).
Breakdown:
Overall Cancer: HR 1.27 (27% ↑), consistent across ages/doses.
mRNA Vaccines: 20% overall ↑; strongest for breast, colorectal, lung, thyroid.
cDNA Vaccines: 47% overall ↑; colorectal, gastric, lung, prostate, thyroid.
Mixed Doses: 34% overall ↑; breast, thyroid.
Demographics: Under-65s vulnerable to thyroid/breast; over-75s to prostate. Women hit harder on colorectal/thyroid; men on gastric/lung.
The linear risk rise over time, steeper for vaccinated, alarms experts like Dr. Clayton Baker: "It could go on for decades." Authors hypothesise spike protein's inflammatory/mutagenic effects, shared with SARS-CoV-2's oncogenic potential (e.g., renin-angiotensin disruption). Statistical power? A "1 in 1,000" chance of fluke, per John Campbell.
| Cancer Type | Risk Increase (HR) | Vaccine Platform Notes |
| Overall | 27% | All types/doses |
| Breast | 20% | mRNA/mixed; women under 65 |
| Colorectal | 28% | All; women higher |
| Gastric | 34% | cDNA; boosters +23%; men |
| Lung | 53% | All; men |
| Prostate | 69% | cDNA; over-75s |
| Thyroid | 35% | All; under-65s |
Expert Endorsements: "Carcinogenic" Spike Protein Under Fire
Hulscher calls it plain: "Both platforms appear carcinogenic," urging withdrawal since "no technology was free." Dalgleish, a UK oncologist, flags spike as "directly carcinogenic," noting boosters' "unexpected" surges mirror UK trends. Campbell praises the scale ("largest yet") and South Korea's reliable data. Baker suspects immune impairment: "Disrupt anti-cancer mechanisms, and cancers manifest fast." Jablonowski counters bias critiques: Differentiating platforms rules out "healthy user" effects.
This aligns with Italian EXCLI Journal findings: 23% cancer hospitalization ↑ post-1/2 doses; +9% after 3+ in ~300,000 over 30 months, hitting breast/bladder/colorectal. Japanese data: Excess deaths ↑ post-jab. Czech fertility drop in vaccinated women. Mechanisms? Spike-induced hyperinflammation or DNA contaminants.
Broader Implications: Calls for Suspension and Global Scrutiny
Hulscher: "Indefensible" to continue boosters; withdraw products. Dalgleish: Spike's carcinogenicity demands halt. With 70% global vax coverage, risks could slash life expectancy (0.8-2 years per 10% multi-cancer ↑). Prioritise gastric monitoring post-boosters. As Italian corroboration grows, this signals a need for pause, if not banning the COVD vax, on this basis alone.